Gsg Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
as on 08-12-2024
- Paid Up Capital ₹ 10.00 Cr
as on 08-12-2024
- Company Age 3 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Revenue %
(FY 2023)
- Profit -16500.00%
(FY 2023)
- Net Worth 3949780.00%
(FY 2023)
- Total Assets 987970.00%
(FY 2023)
About Gsg Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 10.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Gsg Pharmaceuticals Private Limited India is Nimrit Kasturi as COMPANY SECRETARY. Apurva Shah, Om Tyagi, and Tushar Kumar serve as directors at the Company.
- CIN/LLPIN
U24290MH2021PTC371034
- Company No.
371034
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Nov 2021
- Date of AGM
16 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Gsg Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Nimrit Kasturi | Company Secretary | 27-Mar-2024 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Om Tyagi  | Director | 08-Nov-2021 | Current |
| Apurva Shah | Director | 12-Sep-2022 | Current |
| Tushar Kumar | Director | 08-Nov-2021 | Current |
Financial Performance of Gsg Pharmaceuticals.
Gsg Pharmaceuticals Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 16500% decrease in profit. The company's net worth Soared by an impressive increase of 3949780%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Gsg Pharmaceuticals?
In 2023, Gsg Pharmaceuticals had a public holding of 100.01%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Omsav Pharma Research Private LimitedActive 8 years 10 monthsOm Tyagi and Tushar Kumar are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Gsg Pharmaceuticals?
Gsg Pharmaceuticals has a workforce of 0 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Gsg Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Gsg Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
